The Centre has taken measures to address non-compliance with quality control norms in the pharmaceutical industry. Production of drugs has been halted at 31 firms, and licenses of 50 firms have been cancelled or suspended. Showcause notices have been sent to 73 firms, and warning letters have been issued to 21 firms.
These actions are a response to concerns about the production of substandard, adulterated, or fake drugs. Regulatory bodies have conducted inspections at drug manufacturing units across the country to identify those at risk. The focus has been on products such as cold and cough syrups that are exported abroad.
To ensure adherence to the Drugs & Cosmetics Act, 1940 and its rules, a committee of two joint drug controllers has been established at the headquarters of the Central Drug Standard Control Organisation. This committee is responsible for overseeing the inspection process, reporting, and subsequent action.
In light of these developments, Union Minister of Chemicals and Fertilisers, Mansukh Mandaviya, held a meeting with representatives from various pharmaceutical companies. During the meeting, he emphasized the importance of MSME pharma companies prioritizing drug quality and implementing good manufacturing practices through self-regulation.
Mandaviya also instructed the DCGI to take strict action against any companies involved in the production of fake drugs. He emphasized the need for uncompromising quality in drugs manufactured in India.
